INTRODUCTION
Contributed by: Daniel Lim, Steven Baldwin and Jin Ooi, Kirkland & Ellis International LLP
Kirkland & Ellis International LLP has a patent litiga ‑ tion practice comprising approximately 230 attorneys in London, Austin, Boston, Chicago, Dallas, Houston, Los Angeles, Miami, New York, Salt Lake City, San Francisco and Washington, DC. More than 70% of Kirkland’s patent litigation attorneys are engineers and scientists, trained in a variety of technical disci ‑ plines. Kirkland’s experienced IP litigation attorneys achieve extraordinary results in patent, copyright, trade mark, trade secret misappropriation and adver ‑ tising matters. They represent clients across a broad range of industries, including life sciences, technol ‑
ogy, consumer products manufacturing, financial services, automotive, and food and beverage. Other areas of practice are pharmaceutical and biologics patent litigation, co-ordinating global IP enforce ‑ ment/defence cases, SEPs and FRAND disputes, post-grant proceedings before the US Patent and Trademark Office’s Patent Trial and Appeal Board, and appeals of high-stakes cases in the US Court of Appeals for the Federal Circuit and the US Supreme Court, as well as the Court of Appeal of England and Wales and the UK Supreme Court. farm” cases and has a strategic approach to litigation, finding novel solutions to complex problems facing his clients. Steven’s case experience covers a broad range of technical fields, including mobile telecommunications technologies, algorithmic trading, biological and chemical product development and screening platforms, next- generation cancer treatments and e-cigarette/vaping technologies.
Authors
Daniel Lim is a partner in Kirkland & Ellis International LLP’s IP litigation practice in London, where he focuses on high-stakes life sciences patent litigation – particularly with regard to diagnostics, precision medicine, cell
and gene therapy, and the pharmaceutical industry. His case experience includes oncology, molecular biology, diagnostics, antibody engineering and biostatistics, and often involves issues at the cutting edge of the law – notably in relation to second medical-use patents. He is active as a member of the International Association for the Protection of Intellectual Property (AIPPI) and the European Patent Lawyers Association (EPLAW), including as vice- chair of AIPPI’s standing committee on biotechnology.
Jin Ooi is a patent litigator at Kirkland & Ellis. He has worked on matters in the pharmaceutical, chemistry, biotech and life sciences fields (second medical use, biologics/ biosimilars, small molecules, DNA
sequencing, vaccines, and transgenic animal platforms for antibody discovery), in the medical device space (cochlear implants, and bone cements), and in the FMCG and consumer products sector (reduced-risk products including tobacco heating products and e-cigarettes, shaving razors, dishwashing tablets, and coffee pods and capsules). Jin’s cases are often multi-jurisdictional, requiring significant cross-border co-ordination across multiple forums. His dual qualifications in law and pharmacology give him a special insight into, and understanding of, his clients’ legal needs and commercial and regulatory imperatives.
Steven Baldwin is a partner in Kirkland & Ellis International LLP’s IP litigation team in London, with significant experience representing clients in trade secrets, patent, life sciences regulatory, copyright and
trade mark matters. Focusing on former employee trade secrets cases and complex cross-border life sciences and telecommunications patent disputes, Steven’s trade secrets experience includes high- value disputes in the life sciences and financial industries. He is routinely instructed on “bet-the-
4 CHAMBERS.COM
Powered by FlippingBook